8/12/2022  7:14:46 PM Chg. +2.41 Volume Bid7:14:53 PM Ask7:14:53 PM Market Capitalization Dividend Y. P/E Ratio
220.75USD +1.10% 17,952
Turnover: 3.96 mill.
201.96Bid Size: 100 239.95Ask Size: 110 31.67 bill.USD 0.00% 20.90

Business description

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
 

Management board & Supervisory board

CEO
Michel Vounatsos
Management board
Michael McDonnell, Alphonse Galdes, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander
Supervisory board
Dr. Stelios Papadopoulos, Caroline Dorsa, Dr. Alexander J. Denner, Dr. Richard C. Mulligan, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Michel Vounatsos, Stephen A. Sherwin, William A. Hawkins, William D. Jones
 

Company data

Name: Biogen Inc.
Address: 225 Binney Street,Cambridge, Massachusetts 02142, USA
Phone: +1-671-679-2000
Fax: +1-617-679-2617
E-mail: -
Internet: www.biogen.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 72.20%
IPO date: -

Investor relations

Name: Joe Mara
IR phone: +1-781-464-2442
IR Fax: -
IR e-mail: IR@biogenidec.com

Main Shareholders

Freefloat
 
72.20%
PRIMECAP Management Company
 
10.70%
BlackRock, Inc.
 
9.30%
The Vanguard Group
 
7.80%